Pharma & Healthcare
Global Recombinant Uricase Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 561273
- Pages: 121
- Figures: 124
- Views: 1
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Recombinant Uricase market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Horizon Therapeutics
Sanofi
Segment by Type
Pegloticase
Rasburicase
Other
Segment by Application
Gout
Cancer
Kidney Stones
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Recombinant Uricase study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Recombinant Uricase market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Horizon Therapeutics
Sanofi
Segment by Type
Pegloticase
Rasburicase
Other
Segment by Application
Gout
Cancer
Kidney Stones
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Recombinant Uricase study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Recombinant Uricase: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Recombinant Uricase Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Pegloticase
1.2.3 Rasburicase
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Recombinant Uricase Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Gout
1.3.3 Cancer
1.3.4 Kidney Stones
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Uricase Revenue Estimates and Forecasts 2020-2031
2.2 Global Recombinant Uricase Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Recombinant Uricase Sales Estimates and Forecasts 2020-2031
2.4 Global Recombinant Uricase Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Recombinant Uricase Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Recombinant Uricase Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Pegloticase Market Size by Manufacturers
3.6 Global Recombinant Uricase Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Recombinant Uricase Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Recombinant Uricase Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Recombinant Uricase Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Recombinant Uricase Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Recombinant Uricase Sales and Revenue by Type (2020-2031)
6.4 North America Recombinant Uricase Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Recombinant Uricase Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Recombinant Uricase Sales and Revenue by Type (2020-2031)
7.4 Europe Recombinant Uricase Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Recombinant Uricase Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Recombinant Uricase Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Recombinant Uricase Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Recombinant Uricase Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Recombinant Uricase Sales and Revenue by Type (2020-2031)
9.4 Central and South America Recombinant Uricase Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Recombinant Uricase Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Recombinant Uricase Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Recombinant Uricase Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Recombinant Uricase Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Horizon Therapeutics
11.1.1 Horizon Therapeutics Corporation Information
11.1.2 Horizon Therapeutics Business Overview
11.1.3 Horizon Therapeutics Recombinant Uricase Product Models, Descriptions and Specifications
11.1.4 Horizon Therapeutics Recombinant Uricase Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Horizon Therapeutics Recombinant Uricase Sales by Product in 2024
11.1.6 Horizon Therapeutics Recombinant Uricase Sales by Application in 2024
11.1.7 Horizon Therapeutics Recombinant Uricase Sales by Geographic Area in 2024
11.1.8 Horizon Therapeutics Recombinant Uricase SWOT Analysis
11.1.9 Horizon Therapeutics Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Recombinant Uricase Product Models, Descriptions and Specifications
11.2.4 Sanofi Recombinant Uricase Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Recombinant Uricase Sales by Product in 2024
11.2.6 Sanofi Recombinant Uricase Sales by Application in 2024
11.2.7 Sanofi Recombinant Uricase Sales by Geographic Area in 2024
11.2.8 Sanofi Recombinant Uricase SWOT Analysis
11.2.9 Sanofi Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Recombinant Uricase Industry Chain
12.2 Recombinant Uricase Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Recombinant Uricase Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Recombinant Uricase Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Recombinant Uricase Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Recombinant Uricase Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Recombinant Uricase: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Recombinant Uricase Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Pegloticase
1.2.3 Rasburicase
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Recombinant Uricase Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Gout
1.3.3 Cancer
1.3.4 Kidney Stones
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Uricase Revenue Estimates and Forecasts 2020-2031
2.2 Global Recombinant Uricase Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Recombinant Uricase Sales Estimates and Forecasts 2020-2031
2.4 Global Recombinant Uricase Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Recombinant Uricase Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Recombinant Uricase Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Pegloticase Market Size by Manufacturers
3.6 Global Recombinant Uricase Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Recombinant Uricase Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Recombinant Uricase Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Recombinant Uricase Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Recombinant Uricase Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Recombinant Uricase Sales and Revenue by Type (2020-2031)
6.4 North America Recombinant Uricase Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Recombinant Uricase Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Recombinant Uricase Sales and Revenue by Type (2020-2031)
7.4 Europe Recombinant Uricase Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Recombinant Uricase Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Recombinant Uricase Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Recombinant Uricase Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Recombinant Uricase Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Recombinant Uricase Sales and Revenue by Type (2020-2031)
9.4 Central and South America Recombinant Uricase Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Recombinant Uricase Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Recombinant Uricase Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Recombinant Uricase Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Recombinant Uricase Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Horizon Therapeutics
11.1.1 Horizon Therapeutics Corporation Information
11.1.2 Horizon Therapeutics Business Overview
11.1.3 Horizon Therapeutics Recombinant Uricase Product Models, Descriptions and Specifications
11.1.4 Horizon Therapeutics Recombinant Uricase Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Horizon Therapeutics Recombinant Uricase Sales by Product in 2024
11.1.6 Horizon Therapeutics Recombinant Uricase Sales by Application in 2024
11.1.7 Horizon Therapeutics Recombinant Uricase Sales by Geographic Area in 2024
11.1.8 Horizon Therapeutics Recombinant Uricase SWOT Analysis
11.1.9 Horizon Therapeutics Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Recombinant Uricase Product Models, Descriptions and Specifications
11.2.4 Sanofi Recombinant Uricase Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Recombinant Uricase Sales by Product in 2024
11.2.6 Sanofi Recombinant Uricase Sales by Application in 2024
11.2.7 Sanofi Recombinant Uricase Sales by Geographic Area in 2024
11.2.8 Sanofi Recombinant Uricase SWOT Analysis
11.2.9 Sanofi Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Recombinant Uricase Industry Chain
12.2 Recombinant Uricase Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Recombinant Uricase Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Recombinant Uricase Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Recombinant Uricase Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Recombinant Uricase Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Recombinant Uricase Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Recombinant Uricase Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Recombinant Uricase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Recombinant Uricase Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Recombinant Uricase Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Recombinant Uricase Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
Table 7. Global Recombinant Uricase Sales by Region (2020-2025) & (K Dose)
Table 8. Global Recombinant Uricase Sales by Region (2026-2031) & (K Dose)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Recombinant Uricase Sales by Manufacturers (2020-2025) & (K Dose)
Table 11. Global Recombinant Uricase Sales Share by Manufacturers (2020-2025)
Table 12. Global Recombinant Uricase Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Recombinant Uricase Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Recombinant Uricase by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Uricase as of 2024)
Table 16. Global Recombinant Uricase Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Recombinant Uricase Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
Table 18. Key Manufacturers Recombinant Uricase Manufacturing Base and Headquarters
Table 19. Global Recombinant Uricase Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Recombinant Uricase Sales by Type (2020-2025) & (K Dose)
Table 23. Global Recombinant Uricase Sales by Type (2026-2031) & (K Dose)
Table 24. Global Recombinant Uricase Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Recombinant Uricase Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Recombinant Uricase ASP by Type (2020-2031) & (US$/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Recombinant Uricase Sales by Application (2020-2025) & (K Dose)
Table 29. Global Recombinant Uricase Sales by Application (2026-2031) & (K Dose)
Table 30. Recombinant Uricase High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Recombinant Uricase Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Recombinant Uricase Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Recombinant Uricase ASP by Application (2020-2031) & (US$/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Recombinant Uricase Growth Accelerators and Market Barriers
Table 37. North America Recombinant Uricase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Recombinant Uricase Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Recombinant Uricase Growth Accelerators and Market Barriers
Table 40. Europe Recombinant Uricase Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Recombinant Uricase Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Recombinant Uricase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Recombinant Uricase Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Recombinant Uricase Growth Accelerators and Market Barriers
Table 45. Southeast Asia Recombinant Uricase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Recombinant Uricase Investment Opportunities and Key Challenges
Table 47. Central and South America Recombinant Uricase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Recombinant Uricase Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Recombinant Uricase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Horizon Therapeutics Corporation Information
Table 51. Horizon Therapeutics Description and Major Businesses
Table 52. Horizon Therapeutics Product Models, Descriptions and Specifications
Table 53. Horizon Therapeutics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 54. Horizon Therapeutics Sales Value Proportion by Product in 2024
Table 55. Horizon Therapeutics Sales Value Proportion by Application in 2024
Table 56. Horizon Therapeutics Sales Value Proportion by Geographic Area in 2024
Table 57. Horizon Therapeutics Recombinant Uricase SWOT Analysis
Table 58. Horizon Therapeutics Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Recombinant Uricase SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Key Raw Materials Distribution
Table 69. Raw Materials Key Suppliers
Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 71. Milestones in Production Technology Evolution
Table 72. Distributors List
Table 73. Market Trends and Market Evolution
Table 74. Market Drivers and Opportunities
Table 75. Market Challenges, Risks, and Restraints
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Uricase Product Picture
Figure 2. Global Recombinant Uricase Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Pegloticase Product Picture
Figure 4. Rasburicase Product Picture
Figure 5. Other Product Picture
Figure 6. Global Recombinant Uricase Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Gout
Figure 8. Cancer
Figure 9. Kidney Stones
Figure 10. Other
Figure 11. Recombinant Uricase Report Years Considered
Figure 12. Global Recombinant Uricase Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 14. Global Recombinant Uricase Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Recombinant Uricase Revenue Market Share by Region (2020-2031)
Figure 16. Global Recombinant Uricase Sales (2020-2031) & (K Dose)
Figure 17. Global Recombinant Uricase Sales (CAGR) by Region (2020-2031) (K Dose)
Figure 18. Global Recombinant Uricase Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Recombinant Uricase Sales Volume Market Share in 2024
Figure 20. Global Recombinant Uricase Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Pegloticase Revenue Market Share by Manufacturer in 2024
Figure 23. Rasburicase Revenue Market Share by Manufacturer in 2024
Figure 24. Other Revenue Market Share by Manufacturer in 2024
Figure 25. Global Recombinant Uricase Sales Market Share by Type (2020-2031)
Figure 26. Global Recombinant Uricase Revenue Market Share by Type (2020-2031)
Figure 27. Global Recombinant Uricase Sales Market Share by Application (2020-2031)
Figure 28. Global Recombinant Uricase Revenue Market Share by Application (2020-2031)
Figure 29. North America Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 30. North America Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 32. North America Recombinant Uricase Sales Volume (K Dose) by Type (2020- 2031)
Figure 33. North America Recombinant Uricase Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 35. North America Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 40. Europe Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 42. Europe Recombinant Uricase Sales Volume (K Dose) by Type (2020-2031)
Figure 43. Europe Recombinant Uricase Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 45. Europe Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 47. France Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 52. Asia-Pacific Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Recombinant Uricase Sales Volume (K Dose) by Type (2020- 2031)
Figure 55. Asia-Pacific Recombinant Uricase Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 57. Asia-Pacific Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 62. India Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 64. Central and South America Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Recombinant Uricase Sales Volume (K Dose) by Type (2021-2031)
Figure 67. Central and South America Recombinant Uricase Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 69. Central and South America Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 73. Middle East and Africa Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Recombinant Uricase Sales Volume (K Dose) by Type (2021-2031)
Figure 76. South America Recombinant Uricase Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 78. Middle East and Africa Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 83. Recombinant Uricase Industry Chain Mapping
Figure 84. Regional Recombinant Uricase Manufacturing Base Distribution (%)
Figure 85. Global Recombinant Uricase Production Market Share by Region (2020-2031)
Figure 86. Recombinant Uricase Production Process
Figure 87. Regional Recombinant Uricase Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
Table 1. Global Recombinant Uricase Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Recombinant Uricase Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Recombinant Uricase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Recombinant Uricase Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Recombinant Uricase Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Recombinant Uricase Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
Table 7. Global Recombinant Uricase Sales by Region (2020-2025) & (K Dose)
Table 8. Global Recombinant Uricase Sales by Region (2026-2031) & (K Dose)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Recombinant Uricase Sales by Manufacturers (2020-2025) & (K Dose)
Table 11. Global Recombinant Uricase Sales Share by Manufacturers (2020-2025)
Table 12. Global Recombinant Uricase Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Recombinant Uricase Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Recombinant Uricase by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Uricase as of 2024)
Table 16. Global Recombinant Uricase Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Recombinant Uricase Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
Table 18. Key Manufacturers Recombinant Uricase Manufacturing Base and Headquarters
Table 19. Global Recombinant Uricase Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Recombinant Uricase Sales by Type (2020-2025) & (K Dose)
Table 23. Global Recombinant Uricase Sales by Type (2026-2031) & (K Dose)
Table 24. Global Recombinant Uricase Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Recombinant Uricase Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Recombinant Uricase ASP by Type (2020-2031) & (US$/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Recombinant Uricase Sales by Application (2020-2025) & (K Dose)
Table 29. Global Recombinant Uricase Sales by Application (2026-2031) & (K Dose)
Table 30. Recombinant Uricase High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Recombinant Uricase Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Recombinant Uricase Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Recombinant Uricase ASP by Application (2020-2031) & (US$/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Recombinant Uricase Growth Accelerators and Market Barriers
Table 37. North America Recombinant Uricase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Recombinant Uricase Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Recombinant Uricase Growth Accelerators and Market Barriers
Table 40. Europe Recombinant Uricase Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Recombinant Uricase Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Recombinant Uricase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Recombinant Uricase Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Recombinant Uricase Growth Accelerators and Market Barriers
Table 45. Southeast Asia Recombinant Uricase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Recombinant Uricase Investment Opportunities and Key Challenges
Table 47. Central and South America Recombinant Uricase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Recombinant Uricase Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Recombinant Uricase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Horizon Therapeutics Corporation Information
Table 51. Horizon Therapeutics Description and Major Businesses
Table 52. Horizon Therapeutics Product Models, Descriptions and Specifications
Table 53. Horizon Therapeutics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 54. Horizon Therapeutics Sales Value Proportion by Product in 2024
Table 55. Horizon Therapeutics Sales Value Proportion by Application in 2024
Table 56. Horizon Therapeutics Sales Value Proportion by Geographic Area in 2024
Table 57. Horizon Therapeutics Recombinant Uricase SWOT Analysis
Table 58. Horizon Therapeutics Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Recombinant Uricase SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Key Raw Materials Distribution
Table 69. Raw Materials Key Suppliers
Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 71. Milestones in Production Technology Evolution
Table 72. Distributors List
Table 73. Market Trends and Market Evolution
Table 74. Market Drivers and Opportunities
Table 75. Market Challenges, Risks, and Restraints
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Uricase Product Picture
Figure 2. Global Recombinant Uricase Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Pegloticase Product Picture
Figure 4. Rasburicase Product Picture
Figure 5. Other Product Picture
Figure 6. Global Recombinant Uricase Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Gout
Figure 8. Cancer
Figure 9. Kidney Stones
Figure 10. Other
Figure 11. Recombinant Uricase Report Years Considered
Figure 12. Global Recombinant Uricase Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 14. Global Recombinant Uricase Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Recombinant Uricase Revenue Market Share by Region (2020-2031)
Figure 16. Global Recombinant Uricase Sales (2020-2031) & (K Dose)
Figure 17. Global Recombinant Uricase Sales (CAGR) by Region (2020-2031) (K Dose)
Figure 18. Global Recombinant Uricase Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Recombinant Uricase Sales Volume Market Share in 2024
Figure 20. Global Recombinant Uricase Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Pegloticase Revenue Market Share by Manufacturer in 2024
Figure 23. Rasburicase Revenue Market Share by Manufacturer in 2024
Figure 24. Other Revenue Market Share by Manufacturer in 2024
Figure 25. Global Recombinant Uricase Sales Market Share by Type (2020-2031)
Figure 26. Global Recombinant Uricase Revenue Market Share by Type (2020-2031)
Figure 27. Global Recombinant Uricase Sales Market Share by Application (2020-2031)
Figure 28. Global Recombinant Uricase Revenue Market Share by Application (2020-2031)
Figure 29. North America Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 30. North America Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 32. North America Recombinant Uricase Sales Volume (K Dose) by Type (2020- 2031)
Figure 33. North America Recombinant Uricase Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 35. North America Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 40. Europe Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 42. Europe Recombinant Uricase Sales Volume (K Dose) by Type (2020-2031)
Figure 43. Europe Recombinant Uricase Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 45. Europe Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 47. France Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 52. Asia-Pacific Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Recombinant Uricase Sales Volume (K Dose) by Type (2020- 2031)
Figure 55. Asia-Pacific Recombinant Uricase Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 57. Asia-Pacific Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 62. India Recombinant Uricase Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 64. Central and South America Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Recombinant Uricase Sales Volume (K Dose) by Type (2021-2031)
Figure 67. Central and South America Recombinant Uricase Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 69. Central and South America Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Recombinant Uricase Sales YoY (2020-2031) & (K Dose)
Figure 73. Middle East and Africa Recombinant Uricase Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Recombinant Uricase Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Recombinant Uricase Sales Volume (K Dose) by Type (2021-2031)
Figure 76. South America Recombinant Uricase Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Recombinant Uricase Sales Volume (K Dose) by Application (2020-2031)
Figure 78. Middle East and Africa Recombinant Uricase Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Recombinant Uricase Revenue (2020-2025) & (US$ Million)
Figure 83. Recombinant Uricase Industry Chain Mapping
Figure 84. Regional Recombinant Uricase Manufacturing Base Distribution (%)
Figure 85. Global Recombinant Uricase Production Market Share by Region (2020-2031)
Figure 86. Recombinant Uricase Production Process
Figure 87. Regional Recombinant Uricase Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232